Dr. Andrew Piper-Vallillo

Claim this profile

Lahey Hospital and Medical Center

Studies Breast Cancer
Studies Breast cancer
4 reported clinical trials
13 drugs studied

Area of expertise

1Breast Cancer
Andrew Piper-Vallillo has run 3 trials for Breast Cancer. Some of their research focus areas include:
Stage I
Stage II
ER negative
2Breast Cancer
Andrew Piper-Vallillo has run 3 trials for Breast cancer. Some of their research focus areas include:
Stage I
Stage II
ER negative

Affiliated Hospitals

Image of trial facility.
Lahey Hospital And Medical Center
Image of trial facility.
Winchester Hospital

Clinical Trials Andrew Piper-Vallillo is currently running

Image of trial facility.

LY3537982 + Immunotherapy/Chemotherapy

for Non-Small Cell Lung Cancer

This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.
Recruiting1 award Phase 314 criteria
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria

More about Andrew Piper-Vallillo

Clinical Trial Related2 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Andrew Piper-Vallillo has experience with
  • Carboplatin
  • Pembrolizumab
  • Carvedilol
  • Biospecimen Collection
  • Cyclophosphamide
  • Docetaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Andrew Piper-Vallillo specialize in?
Is Andrew Piper-Vallillo currently recruiting for clinical trials?
Are there any treatments that Andrew Piper-Vallillo has studied deeply?
What is the best way to schedule an appointment with Andrew Piper-Vallillo?
What is the office address of Andrew Piper-Vallillo?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security